Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

Author:

Doria A.¹,Stohl W.²,Schwarting A.³,Okada M.⁴,Scheinberg M.⁵,van Vollenhoven R.⁶,Hammer A. E.⁷,Groark J.⁸,Bass D.⁸,Fox N. L.⁹,Roth D.⁸,Gordon D.⁸

Affiliation:

1. University of Padua; Padua Italy

2. University of Southern California; Los Angeles

3. University Medical Center of Johannes Gutenberg University; Mainz Germany

4. St. Luke's International University; Tokyo Japan

5. Rheumatology Hospital Abreu Sodre; São Paulo Brazil

6. Amsterdam Rheumatology and Immunology Center; Amsterdam The Netherlands

7. GlaxoSmithKline; Research Triangle Park North Carolina

8. GlaxoSmithKline; Collegeville Pennsylvania

9. GlaxoSmithKline; Rockville Maryland

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference28 articles.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献